CTLA4 and neoplasm: In agreement with previous studies (Holmgaard et al, 2013), the absence of IDO1 did not prevent tumor growth, but increased the efficacy of anti–CTLA-4 antibody (Fig 5A) that was maintained in the presence of Tα1 (Fig 5A).